Insilico Medicine

For the First Time, Quantum-Enhanced Generative AI Generates Viable Cancer Drug Candidates

Retrieved on: 
Tuesday, February 20, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Technology, Software, Artificial Intelligence, Networks, Clinical Trials, Doctor of Philosophy, Computer science, D-Wave, AI, News, IBM, Drug discovery, Foxconn, University, Insilico Medicine, ArXiv, Research, Human, Cancer, Partnership, Medical device

The research points to a promising future of hybrid quantum generative AI for drug discovery using today’s quantum devices.

Key Points: 
  • The research points to a promising future of hybrid quantum generative AI for drug discovery using today’s quantum devices.
  • In the study, the researchers utilized generative AI to develop novel KRAS inhibitors, a critical focus in cancer therapy historically deemed “undruggable” due to its intrinsic biochemical properties.
  • Generative models running on classical hardware, quantum hardware (specifically, a 16-qubit IBM device), and simulated quantum hardware generated one million drug candidates each, which were then filtered algorithmically and by humans.
  • “For the first time ever, we’ve been able to produce real effective drug lead molecules with quantum-enhanced generative AI,” said Christopher Savoie, CEO and co-founder of Zapata AI.

Ocuphire Pharma Strengthens Leadership Team with Key Appointments

Retrieved on: 
Wednesday, February 14, 2024
Opus, Drug development, University, IPO, Biomedicine, Vanderbilt University Medical Center, Biomedical engineering, Pharmacology, Genetics, American Diabetes Association, ARVO, Principal, NIH, Bank, Business development, Diabetic retinopathy, Therapy, Biomarker, Journal, Retina, Vanderbilt University, Biology, Discovery Medicine, Indiana University, OCUP, Roche, Visual impairment, Business, Diabetes, Paratriathlon, Economics, IND, Bank of America, Intelligence, FDA, Fortress Biotech, Doctor of Philosophy, Genentech, Insilico Medicine, Patient, Science, Editorial board, Citigroup, Pharmaceutical industry

FARMINGTON HILLS, Mich., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP) (“Ocuphire”), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the appointments of Ash Jayagopal, Ph.D., M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.

Key Points: 
  • The team is now set and focused on executing our phase 3 program to turn our science into a reality for patients suffering from diabetic retinopathy, the leading cause of blindness in America.
  • I'm excited to work alongside such a talented team and together to take on significant unmet medical needs with compelling science.”
    Dr. Jayagopal added, “I am excited to join the talented Ocuphire team that has a successful track record in drug development and execution.
  • Prior to joining Ocuphire, he served as the Chief Scientific Officer of Opus Genetics.
  • In this role he had scientific and clinical leadership responsibility for Opus’ retinal gene therapy portfolio, including management of discovery, manufacturing, nonclinical development, and clinical development functions.

Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024

Retrieved on: 
Sunday, January 7, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Associate, Baylor College of Medicine, PKMYT1, BRCA, FDA, Breast, Progression-free survival, Society, Insilico Medicine, Cancer, Distinguishing, Translational research, Neck, PLK4, Workforce, Conference, Translation, Biology, IND, Colorectal cancer, MSN, NHT, University, PARP, Doctor of Philosophy, Calendar, District court, Harvard University, Immunotherapy, Food, Johnson & Johnson, NET, Huntsman Corporation, Cell adhesion, Therapy, TKI, USP1, Neoplasm, Experiment, Patient, NCI, Corporation, Baylor University, Huntsman Cancer Institute, Research, Acquisition, Dean (education), Education, Pnet, Head, Shareholder, Share repurchase, PFS, ADC, Pharmaceutical industry

The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.

Key Points: 
  • The preliminary 2023 financial information presented in this press release has not been audited and is subject to change.
  • The complete Exelixis Fourth Quarter and Fiscal Year 2023 Financial Results are planned for release after market on Tuesday, February 6, 2024.
  • Exelixis expects to substantially complete the restructuring in the first quarter of 2024 and recognize a restructuring charge of approximately $25 million.
  • In 2024, the company expects to designate two new programs to DC status, including a small molecule PLK4 inhibitor and an additional ADC.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
Thursday, January 4, 2024
Menarini, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, Neoplasm, CDX, Artificial intelligence, Patient, Safety, Medical imaging

Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.

Key Points: 
  • Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
  • This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
  • Breast cancer is the most commonly diagnosed tumor type and the leading cause of cancer death among women, globally.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
Thursday, January 4, 2024
Menarini, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, Neoplasm, CDX, Artificial intelligence, Patient, Safety, Medical imaging

Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.

Key Points: 
  • Insilico presented data on the novel molecule at the San Antonio Breast Cancer Symposium in early December.
  • This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.
  • Breast cancer is the most commonly diagnosed tumor type and the leading cause of cancer death among women, globally.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.

Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Menarini, Multimedia, Woman, Breast cancer, Breast, PDX, KAT6A, Doctor of Philosophy, Therapy, Insilico Medicine, Cancer, Mutation, CDX, Neoplasm, Patient, Safety, Intelligence, Medical imaging

This is a significant clinical challenge and highlights the urgent need for novel therapies to help overcome treatment resistance.

Key Points: 
  • This is a significant clinical challenge and highlights the urgent need for novel therapies to help overcome treatment resistance.
  • Overexpression of KAT6A correlates with poor clinical outcomes in patients with ER+/HER2- breast cancer, the most common subtype of breast cancer.
  • Insilico presented data on the molecule at the San Antonio Breast Cancer Symposium in early December.
  • Currently, endocrine therapy in combination with CDK4/6 inhibitors is the standard treatment for ER+/HER2- breast cancer patients with advanced or metastatic disease.

Unlocking the Fountain of Longevity: Longevity Investors Lunch Returns to Davos During WEF, Where Innovation Meets Investment in the Pursuit of Timeless Opportunities

Retrieved on: 
Friday, December 8, 2023
Entrepreneurship, Human Longevity, Conference, Science, Motivation, WEF, Research, Ageless, Health, Education, Insilico Medicine, AI, CPO, MPH, Maximón, Rejuvenation

Zug, Switzerland--(Newsfile Corp. - December 8, 2023) - Longevity Investors Lunch returns for the third edition during the 2024 World Economic Forum (WEF).

Key Points: 
  • Zug, Switzerland--(Newsfile Corp. - December 8, 2023) - Longevity Investors Lunch returns for the third edition during the 2024 World Economic Forum (WEF).
  • The Longevity Investors Conference is the most exclusive conference for longevity investors.
  • "The motivation to organize the Longevity Investors Conference," said Dr. Tobias Reichmuth, Founding Partner and organizer, "is clear: The longevity industry is highly attractive for investors.
  • The Longevity Investors Conference is the most exclusive conference for longevity investors.

Artificial Intelligence in Drug Discovery Market Worth $4.9 Billion | MarketsandMarkets

Retrieved on: 
Monday, November 13, 2023
Cloud, Molecule, CNS, Acquisition, Limited partnership, Investment, Nvidia, Neurology, NVIDIA, Drug discovery, Growth, Demand, Recession, Safety, Toxicity, Workforce, Drug design, Neuroinflammation, Insilico Medicine, AI, Machine learning, Artificial intelligence, Public sector, Merck, Infection, Partnership, Target, Drug development, Process, Research, Microsoft, Disease, Genomics, Illumina, Inc., Medicine, API, Tencent, COVID-19, Pulse, Roche, Google Cloud, Oncology, Pharmaceutical industry, Medical device, Video game, Labcorp, Chemistry, Genentech, Biology

·  By Demand Side: Purchase Managers (45%), Head of Artificial Intelligence, Machine Learning, Drug Discovery, and Computational Molecular Design (30%) and Research Scientists (25%).

Key Points: 
  • ·  By Demand Side: Purchase Managers (45%), Head of Artificial Intelligence, Machine Learning, Drug Discovery, and Computational Molecular Design (30%) and Research Scientists (25%).
  • Artificial Intelligence in Drug Discovery Market - Report Highlights:
    ·  Changes in the scope of the AI in drug discovery market: This latest edition of the report has a newly added segment based on primary and secondary insights, named therapeutic area, process and use case.
  • ·  Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the AI in drug discovery market.
  • ·  Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the AI in drug discovery market.

$11.729 Bn Artificial Intelligence (AI) In Drug Discovery Global Market Opportunities and Strategies to 2032 Featuring Major Players - IBM, Microsoft, NVIDIA, Exscientia, Alphabet, & Atomwis - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 21, 2023
Technology, Pharmaceutical, Health, Artificial Intelligence, Cloud, IBM, Therapy, Prevalence, B2B, Drug discovery, Nvidia, Deep learning, Microsoft, Insilico Medicine, Artificial intelligence, Conditional sentence, Growth, AI, Medical device

The "Artificial Intelligence (AI) In Drug Discovery Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Artificial Intelligence (AI) In Drug Discovery Global Market Opportunities and Strategies to 2032" report has been added to ResearchAndMarkets.com's offering.
  • In the historic period, the artificial intelligence (AI) in drug discovery market witnessed significant growth, driven by emerging markets, the increasing prevalence of chronic diseases, and the adoption of AI for cost-efficient drug discovery.
  • The artificial intelligence (AI) in drug discovery market is highly concentrated, with a large number of small players.
  • The artificial intelligence (AI) in drug discovery market size will gain the most in the USA at $700.4 million.

Global Artificial Intelligence (AI) In Drug Discovery Markets, 2017-2022, 2027F, 2032F: Enhancing Drug Target Selection, Drug Screening Process, & Multi-Omics Data Integration Leading Innovations

Retrieved on: 
Thursday, September 14, 2023
Cloud, IBM, Therapy, Prevalence, B2B, Drug discovery, Nvidia, Deep learning, Microsoft, Insilico Medicine, Artificial intelligence, Conditional sentence, Growth, AI, Medical device

In the historic period, the artificial intelligence (AI) in drug discovery market witnessed significant growth, driven by emerging markets, the increasing prevalence of chronic diseases, and the adoption of AI for cost-efficient drug discovery.

Key Points: 
  • In the historic period, the artificial intelligence (AI) in drug discovery market witnessed significant growth, driven by emerging markets, the increasing prevalence of chronic diseases, and the adoption of AI for cost-efficient drug discovery.
  • North America was the largest region in the artificial intelligence (AI) in drug discovery market, accounting for 41.9% of the total in 2022.
  • The artificial intelligence (AI) in drug discovery market is highly concentrated, with a large number of small players.
  • The artificial intelligence (AI) in drug discovery market size will gain the most in the USA at $700.4 million.